ArticleMaterials today. Bio2025
Metal-phenolic encapsulation of carbon monoxide releasing molecule for enhanced gas therapy of periodontitis.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontitis is an infectious disease caused by plaque-associated microorganisms. The condition is characterized by the activation of oxidative stress and immune responses, which contribute to tissue destruction. Carbon monoxide (CO)-based gas therapy, utilizing CO releasing molecules (CORMs), presents a promising therapeutic strategy; however, its efficacy is constrained by the short half-life and limited cellular uptake of CORMs. In this study, metal-phenolic networks (MPN) were employed as a carrier to stabilize CORMs via metal-ligand coordination, thereby forming a nanocomplex designated as CO@MPN. This nanocomplex demonstrated effective scavenging of reactive oxygen species (ROS) and exhibited ROS-responsive CO release. Following phagocytosis by macrophages, CO@MPN significantly decreased intracellular ROS levels, reduced the production of inflammatory factors in lipopolysaccharide (LPS)-stimulated macrophages, facilitated macrophage polarization towards the anti-inflammatory M2 phenotype, and activated heme oxygenase-1 (HO-1) to further attenuate inflammation. In murine models of experimental periodontitis, CO@MPN significantly inhibited inflammatory bone loss and exerted macrophage-regulating effects. The findings underscore the potential of ROS-responsive CO gas therapy as a promising strategy for the treatment of periodontitis and the management of other inflammatory diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.